Huntington's disease (HD) is a dominantly inherited progressive neurodegenerative disorder caused by the accumulation of polyglutamine expanded mutant huntingtin as inclusion bodies primarily in the brain. After the discovery of the HD gene, considerable progress has been made in understanding the disease pathogenesis and multiple drug targets have been identified, even though currently there is no effective therapy. Here, we demonstrate that the treatment of topotecan, a brain-penetrating topoisomerase 1 inhibitor, to HD transgenic mouse considerably improved its motor behavioural abnormalities along with a significant extension of lifespan. Improvement of behavioural deficits are accompanied with the significant rescue of their progressively decreased body weight, brain weight and striatal volume. Interestingly, topotecan treatment also significantly reduced insoluble mutant huntingtin load in the HD mouse brain. Finally, we show that topotecan treatment to HD mouse not only inhibits the expression of transgenic mutant huntingtin, but also at the same time induces the expression of Ube3a, an ubiquitin ligase linked to the clearance of mutant huntingtin. These findings suggest that topotecan could be a potential therapeutic molecule to delay the progression of HD.
Introduction
Huntington's disease (HD) is an adult-onset autosomal-dominant progressive neurodegenerative disorder. It is clinically characterized by chorea or abnormal involuntary movements along with cognitive and emotional disturbances (1) (2) (3) . Neuropathological features of HD include progressive loss of a specific group of neurons in the caudate and putamen of the striatum, cerebral cortex, hippocampus and hypothalamus (4) (5) (6) . The disease is caused by the abnormal extension of CAG repeat in the exon 1 of IT15 or HD gene (7) . In the normal individual, CAG repeat length varies from 6-35, while the disease phenotype is concomitant with more than 36 repeats, and there is an inverse connection between CAG repeat length and disease inception (2) . HD gene encodes a 350kDa protein called huntingtin, which is expressed all over the brain, and other body tissues and localized primarily in the cytoplasmic compartment (8, 9) . However, mutant huntingtin particularly its Nterminal fragment containing a polyglutamine (polyQ) repeat has been detected in the form of inclusion mainly in the nucleus and to a lesser extent in other subcellular structures (8, 10, 11) . In fact, proteinaceous inclusion of the mutant disease protein is one of the most common pathological hallmarks of HD and many other polyQ disorders (12, 13) .
After the discovery of the HD gene in 1993, there has been tremendous progress in understanding the disease biology. Extensive studies using cellular models, transgenic animal models and post-mortem HD brain samples discovered multiple abnormalities of cellular function that are connected to the progression of HD. Some of the cellular defects include aberrant interaction and transcriptional dysregulation (14) , mitochondrial dysfunction and oxidative stress (15, 16) , altered the clearance of mutant huntingtin and defect in protein quality control (17) (18) (19) and axonal transport (16, 20) .
Abnormal clearance of the mutant huntingtin is an important aspect of HD pathogenesis and draws considerable attention because enhanced clearance of mutant huntingtin could be having therapeutic implication. Mutant huntingtin has been shown to be degraded by both ubiquitin-proteasome system (UPS) and autophagy (21) (22) (23) . However, slower degradation rate (because of the expanded polyQ stretch) over time leads to a gradual build-up of aggregated mutant huntingtin by exceeding the capability of the proteolytic machinery. Dysfunction in UPS and autophagy could further exaggerate aggregation build-up process and creates a vicious cycle (22, (24) (25) (26) . Clearance of mutant huntingtin or its aggregates through either UPS or autophagy requires ubiquitination, a crucial process, which is regulated by ubiquitin protein ligases that exist in large diversity (27, 28) . To date, several ubiquitin ligases have been implicated in the clearance of mutant huntingtin including CHIP, parkin and Ube3a (29) (30) (31) (32) (33) . Among all these ubiquitin ligases, Ube3a is very interesting because of its imprinted expression. The paternally inherited Ube3a is epigenetically silenced in neuronal tissues (34, 35) and a recent report has demonstrated the reactivation of paternally silenced Ube3a by topoisomerase 1 inhibitors (36) . Since Ube3a is involved in the clearance of mutant huntingtin and its deficiency accelerate HD progression in a mouse model (30, 37) , we assumed that its up-regulation through the inhibition of topoisomerase 1 could be beneficial. Therefore, we tested the effect of topoisomerase 1 inhibitor, topotecan on the progression of HD using a specific mouse model. Topotecan is a semisynthetic water soluble derivative of plant alkaloid camptothecin that can cross the blood brain barrier and long been implicated for cancer chemotherapy (38) . The results of our study shows that the treatment of topotecan significantly improved motor behavioural deficits and delayed the disease progression in R6/2 HD mouse model. We also report that topotecan not only increased the expression of Ube3a but also decreased the level of wild type and mutant transgenic huntingtin.
Results

Treatment of topotecan improved behavioural deficits and increased the lifespan in HD mouse
Since topotecan treatment unsilenced the paternally imprinted Ube3a, which is involved in the clearance of mutant huntingtin as well as synaptic function, we tested the effect of this drug on the rescue of disease phenotype in the R6/2 HD mouse model. We first optimized the tolerable dose of topotecan in mice with minimum gross visible side effect. Based on the literature (39), we chose two different doses (2 and 4 mg/kg body weight) of topotecan that was injected intraperitoneally to 9-week-old HD mice. Each mouse received four doses at 2 days interval. In this experimental paradigm, 2 mg/kg dose was well tolerated, while some mice died at 4 mg/kg dose. Therefore, we selected 2 mg/kg dose to further continue our study without altering the dosing schedule. The result of our study showed that topotecan treatment had no significant effect on the body weight of HD mice that gradually decreased over time as the disease progresses (Fig. 1A) . Interestingly, the average lifespan of HD mice was significantly increased by the treatment of topotecan (Fig. 1B) . Treatment of this drug also significantly improved the motor performance of HD mice as evident from the clasping and rotarod test (Fig. 1C and D) . We further attempted to optimize the dose and duration as well as route of administration of the drug for a better outcome. In another experimental setup, we used tail vein injection to administer the topotecan along with a reduced dose for longer duration. Since the half-life of topotecan is about 3 h in the circulation, we thought that tail vein delivery would result quick access of the drug to the brain. We reduced the dose of topotecan to 0.7 mg/kg, which is nearly equivalent to the human dose (1.5 mg/m 2 ) recommended for the treatment of various types of cancer (40) . Each HD and wild type mouse was given three consecutive doses/week, and the treatment was continued for 3 weeks. In this experimental model, we did not observe any gross visible side effect of this drug on wild type or HD mice. In fact, treatment of topotecan significantly rescued the progressive decrease in body weight of HD mice ( Fig. 2A) . The average survival rate of topotecantreated HD mice was also significantly increased by about 30 days (Fig. 2B) . Topotecan treatment also significantly improved various motor behavioural abnormalities in HD mice compared to age-matched saline-treated control HD group (Fig. 3) . In rotarod test, drug-treated HD mice performed comparatively better than saline-treated HD controls (Fig. 3A) . Abnormal clasping behaviour was also significantly recovered in drug-treated mice group (Fig. 3B) . In gait analysis, HD mice showed abnormally decreased stride length and increased gap between fore and hind paws and those peculiarities were improved upon the treatment of topotecan ( Fig. 3C and D) .
Topotecan exposure partially restored striatal atrophy and decreased aggregate load in the brain of HD mice
Because tail vein injection with low dose of topotecan resulted better behavioural rescue in HD mice, we were interested to know the underlying mechanisms. Topotecan-treated HD and wild type mice along with age-matched saline-treated control group were sacrificed at the end of 12 weeks, and the brain samples were collected for structural and biochemical analysis. Striatal atrophy is one of the classical features of the HD brain. Therefore, we first estimated the striatal volume of drug-treated HD mice along with other groups. Nissl-stained histological section showed dilation of lateral ventricle due to striatal atrophy in saline-treated HD mice, while drug treatment reduced the ventricular enlargement (Fig. 4A ). Striatal volume was also measured stereologically from Nissl-stained coronal brain sections. As shown in Fig. 4B , striatal volume was significantly reduced in 12-week-old HD mice that can be partially rescued by topotecan. Treatment of this drug also partially restored reduced brain weight of HD mice (Fig. 4C ). Next, we studied the aggregate load in different region of topotecan-treated HD mice along with age-matched saline-treated HD controls. Interestingly, the treatment of drug substantially reduced the number of nuclear aggregate in different brain regions of HD mice, which was clearly visible in immunohistochemically stained section using a huntingtin antibody (Fig. 5 ). Even the average size of nuclear aggregate was also comparatively smaller in the drug-treated group. The approximate number of nuclear aggregates in the striatum, motor cortex and hippocampal region of drug-treated HD mice was significantly reduced compared to HD control group (Fig. 6A ). Dot blot analysis of the cortical brain samples using huntingtin antibody also confirmed that topotecan treatment significantly reduced the insoluble mutant protein in HD mice ( Topotecan treatment not only increased the level of Ube3a but also decreased transgenic mutant huntingtin in the HD mouse brain
Intrathecal or intra cerebroventricular administration of topotecan in mice has been shown to up-regulate the expression of Ube3a in the neuron by unsilencing paternally imprinted Ube3a. Ube3a also has been demonstrated to enhance the degradation of mutant huntingtin. Therefore, we suspected that topotecaninduced up-regulation of Ube3a could be linked to decreased aggregate load in HD mice. To confirm our hypothesis, we analysed Ube3a level in the brain sample of saline and topotecan-treated wild type and HD mice. Figure 7A and B shows that topotecan treatment significantly increased the level of Ube3a in the cortex and striatum of HD mice compared to HD control group. Topotecan treatment also increased Ube3a mRNA level in the cortex of HD mice (Fig. 7C) . However, topotecan had no effect on the up-regulation of Ube3a in wild type mice ( Fig. 7) . The reason for this apparent discrepancy is not clear to us. It is conceivable that progressive impairment of blood brain barrier in HD mice might lead to more access of drug to the brain (41) . Figure 7 also shows that topotecan treatment partially restored the decreased level of DARPP32 (a dopamine-regulated phoshpho protein) in HD striatum. Downregulation of DARPP32 in HD mice striatum is well known (42) and its partial restoration indirectly suggests the improvement of disease pathology. Next, we attempted to analyse the level of mutant transgenic huntingtin in the saline and topotecan-treated HD mouse brain samples. We failed to detect soluble mutant huntingtin by using a specific antibody against huntingtin. However, we were able to identify mutant huntingtin using a polyQ domain-specific antibody (1C2 antibody from Millipore). Interestingly, we found that the treatment of topotecan significantly reduced the level of mutant transgenic huntingtin (about 40-45%) in the cortex and striatum of HD mice compared to saline-treated control HD group (Fig. 8A and B) . Real time RT-PCR analysis also showed about 24% decrease in the mRNA level of mutant transgenic huntingtin in the topotecan-treated cortical samples compared to saline-treated control group (HD þ Saline, 1 6 0.8; HD þ Topo, 0.766.04). This result indicates that topotecan could negatively regulate the expression of transgenic mutant huntingtin. Reevaluation of genotyping clearly indicates that the CAG repeat size is similar in all the HD transgenic mice used in the experiment (Supplementary Material, Fig. S1 ). Since transgenic mutant huntingtin expression is driven by huntingtin promoter, topotecan could be able to suppress the expression of wild type huntingtin. To confirm the fact, we analysed the mRNA level of wild type huntingtin and found that topotecan treatment significantly inhibited the expression of wild type huntingtin in the HD mouse brain (Fig. 8C) . Interestingly, topotecan also inhibited the expression of mutant huntingtin in a cellular model of HD where mutant gene is regulated by ecdysone-inducible expression system (Supplementary Material, Fig. S2 ).
Discussion
Topotecan is a water soluble structural analogue of naturally occurring camptothecin that has the ability to penetrate the blood brain barrier. It is a powerful inhibitor of topoisomerase 1 and is approved to treat various types of cancer (38, 40) . Here, we provide several lines of evidence that indicate topotecan has enormous potential to delay the progression of HD. We have not only demonstrated the effect of this drug to rescue the behavioural deficit and increase the survival of HD mice but also at the same time identified the probable underlying mechanism.
Topotecan by the virtue of topoisomerase 1 inhibition (through stabilization of enzyme-DNA complex) prevents DNA unwinding, a crucial event that is required for DNA replication and transcription (43) . Therefore, one could expect severe detrimental effect of this drug not only on rapidly dividing cells like cancer cells, but also on normal differentiated cells like neurons. However, this drug under the specific treatment regime is well tolerated by cancer patients (40, 44) . In our experimental paradigm, we have not seen any lethality or gross visible side effects of this drug when treated to wild type and HD mice. Instead, topotecan treatment actually restored progressive decrease in body weight in HD mice along with a reversal of motor abnormalities. The dose of topotecan that we used in our animal experiment was nearly equivalent to the dose recommended for treating cancer patients (1.5 mg/m 2 ). Adjustment of the dose and duration of topotecan could further improve behavioural abnormalities with minimum side effect.
One of the major reasons of topotecan-mediated suppression of mutant huntingtin aggregation, behavioural rescue and extension of lifespan in HD mice could be down-regulation of mutant huntingtin expression. Because the expression of transgenic mutant huntingtin in R6/2 HD mice is driven by huntingtin promoter, it is expected that the endogenous huntingtin will be downregulated by topotecan and indeed we have confirmed it. Downregulation of mutant huntingtin expression is one of the important strategy to slowdown the HD progression. Selective inhibition of mutant huntingtin expression by either siRNA or antisense oligonucleotide have been shown to be effective in rescuing the disease progression in various animal models of HD (45, 46) . In this regard, small molecule inhibitors of huntingtin expression like topotecan could be a potential therapeutic candidate. However, one should be cautious as wild type huntingtin also plays a very important role in cellular functioning (47, 48) . Recent reports have revealed that topotecan and related topoisomerase 1 inhibitors decreased the expression of exceptionally large genes (>200kb) with minimal effect on most other genes in postmitotic neurons and many of these large genes are linked to synaptic function (49, 50) . In this context, it is important to note that huntingtin is also a large gene (180kb) and linked to synaptic function (47) . However, our data seem to indicate that topotecan-induced down-regulation of huntingtin is independent of its size and promoter context. An earlier study has identified camptothecin as a strong suppressor of mutant huntingtin aggregation and mutant huntingtin-induced toxicity in Drosophila primary neuronal cultures (51) . This could be due to the inhibitory effect of camptothecin on transgenic mutant huntingtin expression, which is under the control of GAL4/UAS system. Up-regulation of Ube3a by topotecan could be another mechanism that is associated with the rescue of behavioural abnormalities and extension of lifespan by enhancing the clearance of mutant huntingtin. Rescue of disease pathology could again indirectly contribute to restore the reduced Ube3a in HD mouse brain and thus could generate positive feedback cycle. Ube3a is a HECT (homologous to E6-AP C-terminus) domain family of ubiquitin ligase linked with cellular protein quality control and synaptic function (52, 53) . It enhances the clearance of mutant huntingtin in the cellular as well as a transgenic mouse model of HD (30, 31) . Furthermore, its level is significantly reduced in the HD mouse brain and removal of Ube3a from HD mice brain increase the disease severity (37) . These findings indicate that Ube3a could be a crucial factor in modulating the progression of HD. Since Ube3a is a paternally imprinted gene primarily in neuronal tissues and its defect causes Angelman syndrome (a neurodevelopmental disorder), several attempts have been made to reactivate the paternally inherited Ube3a for therapeutic benefit (34, 35, 54) . Topoisomerase 1 inhibitors (including topotecan) are one such group of compounds that can potentially reactivate paternally silenced Ube3a in multiple brain regions by preventing the expression of Ube3a antisense transcript. Interestingly, topotecan-induced effect on Ube3a can be observed even 12 weeks after the termination of the drug (36) . In our experimental paradigm, we have detected increased level of Ube3a in the brain of topotecan-treated HD mice but not in wild type mice. This apparent discrepancy could be due the poor penetrating capacity of topotecan into the normal brain (55) . But in the HD mouse brain, there are reports of leakage in blood brain barrier and that could result increased access of topotecan into the brain (41) .
Interestingly, topotecan-mediated down-regulation of huntingtin as well as up-regulation of Ube3a are two crucial events that are extremely beneficial in the context of HD. Same drug could not only inhibit the expression but also enhance the clearance of mutant huntingtin leading to decrease in aggregate burden. The potential side effect of other abnormally regulated genes could be minimized by optimizing the dose and duration of the drug. Since many of the negatively regulated genes are linked to synaptic function, their effect could be counter balanced by increased expression of Ube3a or other imprinted genes performing similar functions. Altogether, our study provides strong evidence that topotecan could be a potential therapeutic molecule to delay the progression of HD.
Materials and Methods
Materials
Rabbit polyclonal anti-Ube3a (SC-25509), goat polyclonal antihuntingtin (SC8767) and rabbit polyclonal anti-DARPP32 (SC11365) were purchased from Santa Cruz Biotechnology. Topotecan, camptothecin and mouse monoclonal anti-b-actin (A5316) were from Sigma. Mouse monoclonal anti-1C2 (MAB1574) was from Millipore. Alkaline phosphatase and horse radish peroxidase and biotin-conjugated secondary antibodies and ABC kit were purchased from Vector Laboratories.
Animals and drug treatment
HD transgenic mice (strain B6CBA-Tg (HDexon1) 62Gpb/3J) were purchased from The Jackson Laboratory and maintained in our animal house facility. This transgenic mouse line (often called R6/2 line) was generated by introducing 5'-end of the human HD gene containing promoter sequence and Exon1 carrying 120 CAG repeats. This R6/2 transgenic mouse model exhibits a rapidly progressive neurological phenotype very similar to human HD (56) . Animals had free access to a pelleted diet and water ad libitum. All animal experimentation was performed according the Institutional guidelines for the use and care of animals and all experimental protocols were approved by the Institutional Animal Ethics Committee of the National Brain Research Centre. PCR-based genotyping protocol was adapted from the earlier studies (56) . After genotyping, female HD mice along with their wild type female littermates were used for experimental purpose. Topotecan was dissolved in saline and was injected to wild type or HD mice at their age of 9 weeks. For intraperitoneal injection, topotecan was used at a dose of 2 mg/ kg body weight and each mouse was received four injections at 2 days interval. For tail vein injection, topotecan was used at a dose of 0.7 mg/kg body weight and each mouse received total 9 doses with 3 consecutive doses per week (9, 10 and 11 weeks). Control mice were injected with the same volume of saline.
Mice were regularly monitored for their body weight and various motor tests up to the age of 12 weeks and then either left for survival studies or sacrificed for various biochemical experimentation.
Behavioural experiments
Clasping test
The test was conducted by hanging the tail of mice to see when their limbs are firmly close together. Each mouse was assessed for 3 trials (each 60 s duration) per experimental time point. Clasping scores were assigned as follows: 0, no clasping in 60s; 1, clasping in 31-60s; 2, clasping in 16-30s; 3, clasping 11-15s, 4, clasping in 06-10s; 5, clasping 1-5s. All tests were performed in a blinded fashion.
Gait analysis
For foot-print gait analysis, the fore and hind paws of the mice were immersed in different colour nontoxic inks. The mice were then allowed to walk on a wooden tunnel (40 Â 5 cm) lined with white paper. The mice were trained for 3 days to walk through the tunnel and then tested for three trials. Stride length and distance between fore and hind paws were then measured from the middle portion of their walking footprint.
Rotarod test
Mice were placed on the rotarod instrument and initially trained to walk on the rotating rod with a constant speed of 5 rpm. Mice were trained for 3 days and then tested for three trials in each week at a constant rod speed of 10 rpm. Average time of three trials for each mouse in each week was calculated to generate the overall time for each mouse. Maximum time allowed to complete rotarod task is 60 s.
Measurement of striatal volume
Mice were anaesthetized and transcardially perfused with 4% paraformaldehyde in PBS and brains were carefully removed. Brain samples were then processed for cryo-sectioning using freezing microtome and serial coronal sections (20 lm thickness) were subjected for Nissl staining. The stereological volume of striatum was measured in random sections of an orderly set (e.g. every 5
th section with the first section selected randomly among first five sections) from the anterior of the striatum to levels slightly posterior to the level of the crossing of the anterior commissure. The boundary of the striatum was outlined in each Nissl stained image (1Â) in the NeuroLucida software. Subsequently, total striatal volume was calculated according to the earlier described procedure (57) .
Immunostaining and aggregates counting
Paraformaldehyde-fixed brains were processed for cryosectioning to obtain 20 mm thick sections. The sections were then subjected to antigen retrieval for 45 min at 70 C, washed with PBS, blocked with normal goat serum, and then incubated overnight with huntingtin antibody (anti-goat at 1:100 dilutions). Biotinylated secondary antibody was used at a dilution of 1:500, and the signal was enhanced using ABC reagent and developed using ImmPACT Novared Peroxidase Substrate. Stained sections were observed in a Leica DM RXA2 microscope and digital images were obtained. Total number of huntingtin positive aggregates was counted in multiple random sections of 40x magnification (0.200 Â 0.150 mm area) from the motor cortex, striatum and hippocampal region of the brain.
Immunoblotting and dot blot assay
Mice were sacrificed by cervical dislocation. Cortical and striatal parts of the brain were carefully dissected out and homogenised in RIPA lysis buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS and complete protease inhibitor cocktail) and were kept on ice for 30 min. Homogenized samples were briefly centrifuged at 15,000 x g for 10 min, supernatants were collected, the protein amount in each sample was estimated and stored at À80 C. Stored samples were then processed for SDS-PAGE followed by immunoblotting using various antibodies as described earlier (31) . Primary antibodies for 1C2, Ube3a and DARPP-32 were used at 1:1000 dilutions and b-actin at 1:5000 dilutions. For dot blot assay, cortex samples were homogenized in ice cold homogenization buffer (50 mM Tris, pH, 7.4, 150 mM NaCl, 1% Triton X-100, 1 mM PMSF, and complete protease inhibitor tablet), sonicated for a short time followed by estimation of protein. An equal concentration of each sample (1 mg/120 ml) was treated with DNAse 1 and then centrifuged at 13,000 x g for 15 min. The pellet was collected and treated with 2% SDS at room temperature for 5 min and equal volume of different samples were filtered through nitrocellulose membrane. Membranes were then processed for immunoblotting with huntingtin antibody.
Quantitative real-time RT-PCR
RNA was extracted from wild type and HD mice brains using Trizol reagent (Sigma) following manufacturer protocol. Quantitative real-time RT-PCR for Ube3a, wild type and transgenic huntingtin was performed using power SYBR Green PCR master mix (Applied Biosystems) after cDNA synthesis from total RNA. PCR reaction was carried out using ViiA7 real time PCR system (ABI), and data were subsequently analysed and expressed as fold change. RT-PCR products were normalized with 18S RNA as an internal control. Primer sequences for Ube3a, wild type huntingtin and 18S RNA are as follows: Ube3aF, 
Statistical analysis
Statistical study was conducted with SigmaStat software. Values were analysed by using one or two-way ANOVA followed by Holm-Sidak post-hoc test. In some experiments, two-tailed Student's t-test was used for inter group comparison. Survival data were analysed by Kaplan-Meier survival analysis and multiple curves were compared by log rank test. P < 0.05 was considered statistical significant.
Supplementary Material
Supplementary Material is available at HMG online.
